Invest in the Future of Diabetes Care

We’re developing a stem cell-based cure for diabetes using reprogrammed/differentiated cells from the patient’s own body.

Our approach eliminates the need for insulin and lifelong medications, and we’re preparing for our first preclinical trial.

Why Now

• Diabetes affects over 500 million people worldwide, with healthcare costs topping $850B annually.

• Current treatments manage symptoms, but don’t address the root cause.

• Our approach has the potential to reverse disease, not just slow it down.

Why Us

• Co-founded by Dr. Noel Moya, PhD, one of the few scientists worldwide with expertise in beta cell differentiation.

• Backed by early scientific validation (in vitro and in vivo results from small animal models), patent filings, and partnerships with leading medical clinics.

• We’re ready to go. Our protocols are in place, our team is built, and we’re prepared to begin preclinical pig trials as soon as funding is secured.

What We’re Raising

We’re currently raising funds to support the next phase of development, including:

• Preclinical pig trial

• Regulatory advancement

• Commercial readiness

Let’s Talk

If you’re an investor, fund, or strategic partner interested in transforming diabetes care, view our deck.